VA/DoD Guideline for Managing Dyslipidemia

A U.S. lipid management guideline has been updated to focus on “less is more.”

Sponsoring Organizations: U.S. Department of Veterans Affairs (VA); U.S. Department of Defense (DoD)

Background

In 2015, the VA/DoD issued a guideline on management of dyslipidemia for primary and secondary prevention of cardiovascular disease (CVD) events (NEJM JW Gen Med Aug 1 2015 and Ann Intern Med 2015; 163:291). The guideline has now been updated, with a focus on preventing CVD-related mortality.

Key Recommendations

Treat patients with dyslipidemia to achieve target statin dosing (not to achieve a target LDL cholesterol level), based on 10-year CVD risk.
For primary prevention, prescribe moderate-dose statin therapy for patients with 10-year CVD risk >12%. Proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitors should not be used …

Reviewing Author

Daniel D. Dressler, MD, MSc, MHM, FACP

Disclosures

RoyaltiesMcGraw-Hill; Elsevier

Editorial BoardsMedical Clinics of North America; Caribbean Medical Journal International Advisory Panel (2021–2026)